📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
Blog
Big drug, little drug: Capitalising on large molecule progress
What does progress in the large molecule space mean for small molecule drug…
Blog
Alzheimer’s disease and neurodegeneration: New approaches and advances
In addition to the recent strides made in our molecular and cellular…
Blog
Celebrating women and girls in science
International Day of Women and Girls in Science is always a time…
News
Taking a 3D view of heart failure with River BioMedics
Exciting Collaboration with River BioMedics: Advancing Heart Failure Treatments We’re excited about our partnership with…
Blog
Plasma protein binding: Important, needed, non-optimisable
Dr Richard Weaver, Senior Vice President of Preclinical Development at Sygnature Discovery, shares his thoughts…
Blog
Charles Woler talks drug discovery
Charles Woler joined Sygnature’s board back in January, so it seemed like the right time…
Blog
Drug discovery in a pandemic: A scientist’s view
Andy Novak, a Principal Scientist at Sygnature, reflects on his experiences and the lessons learned…
News
500 – and counting!
When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a…
News
500 – et ce n’est pas fini !
Lorsque Lynette Ongeri, scientifique spécialisée en DMPK, a rejoint Sygnature ce mois-ci, elle nous a…
Blog
About those National Retrosynthesis Competition wins…
What is retrosynthesis? What is the National Retrosynthesis Competition? And how great were our teams…
Blog
Why form & formulation should be embedded in early drug discovery
Brick dust. We’ve all heard the term, but how do we solve the issue?…
Blog
Thoughts on the challenges of treating ovarian cancer
At the American Association for Cancer Research meeting in New Orleans this…
Blog
Covalent drug resurgence: what’s the story?
The idea of designing drugs that form covalent bonds with their targets first emerged in…
News
Sygnature Discovery acquires Peak Proteins
Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the…
Blog
5 things you should know about PROTACs
Explore Sygnature Discovery's comprehensive solutions in drug discovery as we delve into the world of PROTAC® targeted protein degraders.
News
Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’
We are thrilled to announce that we have embarked on a 3-year collaboration agreement with…
Blog
6 Questions to Max Plancks’ Tobias Ritter; solving problems with chemistry
We had a chat with chemist, Prof. Tobias Ritter, of the Max…
Blog
What does “drug-like space” mean to a medicinal chemist?
Introducing Dr. Paul Leeson! Paul is a medicinal chemist and drug discovery…
Blog
Precision Cut Kidney Slices (PCKS) in Chronic Kidney Disease (CKD) to Help Select Better Drug Candidates and Bridge the Translational Gap
Chronic kidney disease (CKD) is a common and debilitating condition which affects an estimated…
Blog
Enhancing Membrane Protein Characterisation: Sygnature, Peak Proteins & Cytiva Collaboration
Advancing the biophysical characterisation of membrane protein targets in drug discovery: A collaboration amongst Sygnature…
Blog
Oncology drug discovery: reflections on current trends
This year’s American Association…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch